Â Â UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549Â FORM 6-KÂ REPORT OF FOREIGN PRIVATE ISSUERPURSUANT TO RULE 13a-16 OR 15d-16UNDER THE SECURITIES EXCHANGE ACT OF 1934Â For the month of February 2025Â Commission file number: 001-38428Â PolyPid Ltd.(Translation of registrantâ€™s name intoEnglish)Â 18 Hasivim StreetPetach Tikva 495376, Israel(Address of principal executive office)Â Indicate by check mark whether the registrantfiles or will file annual reports under cover of Form 20-F or Form 40-F:Â â˜’Form 20-FÂ Â Â Â Â Â Â Â Â Â â˜Form 40-FÂ Â Â Â Â Â CONTENTSÂ Appointment of New DirectorÂ On February 12, 2025, PolyPidLtd. (the â€œCompanyâ€) announced the appointment of Yitzchak Jacobovitz to its Board of Directors (the â€œBoardâ€),effective February 10, 2025.Â Mr. Jacobovitz, age 49, currentlyis a partner at AIGH Capital Management, a position he has held since 2014. He has served as a director at the board of directors of Myomo,Inc. (NYSE American: MYO) since January 2023. Prior to his current positions, Mr. Jacobovitz was a managing director at Capstone, a policyresearch firm, and an analyst at Leap Tide Capital, a special situations hedge fund. Mr. Jacobovitz earned his Masters in Business Administrationfrom Johns Hopkins University and is a Chartered Financial Analyst.Â TheBoard concluded that Mr. Jacobovitz is qualified to serve as a Director and is independent under the rules of the Nasdaq Stock Market.Mr. Jacobovitz has agreed not to receive compensation for his service as a Director. The Company expects to enter into its standard indemnificationagreement with Mr. Jacobovitz, on substantially the same terms as the indemnification agreements previously entered into between the Companyand each of its directors and executive officers. Mr. Jacobovitz is not a party to any transactions that are disclosable under Item 7.Bof Form 20-F.Â Issuance of PressReleaseÂ Attached hereto and incorporatedherein is the Companyâ€™s press release issued on February 12, 2025, titled â€œPolyPid Provides Corporate Update and Reports FourthQuarter 2024 Financial Results.â€Â Thebullet points under the section titled â€œRecent Corporate Highlights,â€ the sections titled â€œFinancial results for threemonths ended December 31, 2024â€, â€œFinancial results for the full year ended December 31, 2024â€, â€œBalance SheetHighlights,â€ and â€œForward-looking Statementsâ€ and the financial statements in the press release are incorporated byreference into the Companyâ€™s registration statements on Form F-3 (File No.Â 333-276826,File No.Â 333-280658Â andFile No.Â 333-281863)and Form S-8 (File No.Â 333-239517,File No.Â 333-271060,File No.Â 333-277703Â andFile No.Â 333-280662)filed with the Securities and Exchange Commission to be a part thereof from the date on which this report is submitted, to the extentnot superseded by documents or reports subsequently filed or furnished.Â Exhibit No. Â Â 99.1 Â Press Release issued by PolyPid Ltd. on February 12, 2025, titled â€œPolyPid Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results.â€ Â 1 Â Â SIGNATURESÂ Pursuant to the requirementsof the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereuntoduly authorized.Â Â POLYPID LTD. Â Â Â Date: February 12, 2025 By: /s/ Dikla Czaczkes Akselbrad Â Â Name:Â Dikla Czaczkes Akselbrad Â Â Title: Chief Executive Officer Â Â 2Â Â Exhibit 99.1Â PolyPid Provides Corporate Update and ReportsFourth Quarter and Full-Year 2024 Financial Results Â Positive Recommendationby DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEXâ,â,€â,€ to 800 PatientsÂ SHIELD II Enrolledmore than 700 Patients to Date; Enrollment Completion Expected in March 2025, with Top-Line Results Anticipated in Second Quarter of 2025Â Company Completed PrivatePlacement of Up to $41 Million; Proceeds and Exercise of Data-Triggered Warrants Expected to Extend Cash Runway Beyond Potential NDA ApprovalÂ Conference Call Scheduled for Today at 8:30AM ETÂ PETACH TIKVA,Â Israel,Â February12, 2025 -- PolyPid Ltd.Â (Nasdaq: PYPD)(â€œPolyPidâ€ or the â€œCompanyâ€), a late-stage biopharma company aiming to improve surgical outcomes, today provideda corporate update and reported financial results for the three months and full year ended December 31, 2024. Â Recent Corporate Highlights:Â â—The independent Data Safety Monitoring Board (â€œDSMBâ€) recommended to concludethe SHIELD II Phase 3 trial of D-PLEX100 upon enrollment of 800 patients in the study , which is the lowest sample size reassessmentstop after the minimum planned number of patients.Â oThe study has enrolled more than 700 patients to date and enrollment of the last patient is expected tooccur in March 2025.Â oThe Company anticipates reporting top-line results in the second quarter of 2025.Â oUpon potential positive Phase 3 data, PolyPid expects to submit a New Drug Application (â€œNDAâ€) with the advantages ofÂ theÂ FastTrack and Breakthrough Therapy designations.Â Â â—Concurrent with the DSMBâ€™s positive recommendation, as previously reported,PolyPid entered into a securities purchase agreement for a private placement financing (â€œPIPEâ€)Â led by existing institutionalÂ shareholdersforÂ $14.5 millionÂ in gross proceeds. Â oUnder the securities purchase agreement, the investors also received warrants which willÂ expire upon the earlier ofÂ ninemonths from the date of issuance and 10 trading days followingÂ PolyPidâ€™s announcementÂ of top-line results from its SHIELDII Phase 3 trial. Exercise of the warrants in full would result in an additionalÂ $27.0 millionÂ in gross proceeds to the Company.Â oThe gross proceeds from the financing extend PolyPidâ€™s cash runway into the third quarter of 2025, beyond expected top-lineresults fromÂ SHIELD II.Â oProceeds of all warrants issued in this transaction, if exercised, would provide the Company with capital beyond NDA approval.Â â—Announced a research and development collaboration with ImmunoGenesis, Inc. which focuses on the developmentof novel formulations utilizing PolyPidâ€™s experience with its proprietary PLEX Technology and ImmunoGenesisâ€™ potent STimulatorof INterferon Genes (â€œSTINGâ€) agonist drug candidate to potentially enhance treatment for solid tumors.Â â—Appointed Mr. Yitzchak Jacobovitz, CFA, to the Board of Directors, effective as of February 10, 2025.Mr. Jacobovitz is a partner and lead healthcare analyst at AIGH Capital Management and affiliates. Mr. Jacobovitz is also a board memberat Myomo, Inc. He earned his MBA from Johns Hopkins University and is a Chartered Financial Analyst.Â Â Â Â â€œWe are thrilledwith the impressive clinical and operational progress achieved in 2024 and believe that we are well-positioned for a potentially transformationalyear in 2025,â€ stated Dikla Czaczkes Akselbrad, PolyPidâ€™s Chief Executive Officer. â€œImportantly, we remain confidentthat the DSMBâ€™s recent recommendation to concludeÂ SHIELD IIÂ upon the enrollment of 800 patientsÂ is suggestiveof positive efficacy signals from D-PLEX100. Moreover, the sample size reassessment was an opportunity to ensure the studyhas sufficient power to conclusively confirm D-PLEX100's treatment benefit, and we believe this increasesÂ the trialâ€™soverall probability of success. We continue to focus on completing the trial, while advancing our planned NDA and Marketing AuthorizationApplication (â€œMAAâ€) submissions, preparing pre-launch activities, and expediting partnership discussions in and outside ofthe United States. We are also excited to welcome Mr. Jacobovitz to the Board of Directors and are pleased that AIGH was the lead investorin our most recent equity offering. Mr. Jacobovitz brings extensive healthcare investment experience to our board and we look forwardto his contributions.â€Â Financial results for three months ended December31, 2024Â â—Research and development (â€œR&Dâ€) expenses for the three months ended December 31, 2024,were $7.0 million, compared to $4.6 million in the same three-month period of 2023. The increase in R&Dexpenses in the most recently completed quarter was driven by the ramp up of the ongoing SHIELD II Phase 3 trial.Â â—General and administrative

(â€œG&Aâ€) expenses for the three months ended December 31, 2024,were $1.0 million, compared to $1.2 million for the same period of 2023.Â â—Marketing and business development expenses for the three months ended December 31, 2024, were $0.2 million,compared to $0.2 million for the same period of 2023.Â â—For the three months ended December 31, 2024, the Company had a net lossofÂ $8.5 million, or ($1.13) per share, compared to a net loss of $6.4 million, or ($3.97) pershare, in the three-month period ended December 31, 2023. Â Financial results for the full year ended December31, 2024 Â â—R&D expenses, net for the twelve months ended December 31, 2024, were $22.8 million, compared to $16.1million for the same twelve-month period of 2023. The increase in R&D expenses was driven by the ramp up of the ongoing SHIELD IIPhase 3 trial.Â â—G&A expenses for the twelve months ended December 31, 2024, were $4.3 million, compared to $5.5 millionfor the same period of 2023.Â â—Marketing and business development expenses for the twelve months ended December 31, 2024, were $0.9 million,compared to $1.2 million for the same period of 2023.Â â—The decreases in G&A and marketing and business development expenses were primarily due to the Companyâ€™songoing cost savings initiatives.Â â—For the twelve months ended December 31, 2024, the Company had a net lossofÂ $29.0 million, or ($4.91) per diluted share, compared to a net loss of $23.9 million, or($16.93) per diluted share, in the twelve-month period ended December 31, 2023. Â Balance Sheet HighlightsÂ Â·As of December 31, 2024, the Company had cash and cash equivalents in the amount of $15.6 million, compared to $5.3 million on December 31, 2023. PolyPid expects that its current cash balance will be sufficient to fund operations into the third quarter of 2025. Â 2 Â Â Conference Call Dial-In & Webcast Information:Â Date:Â Wednesday, February 12, 2025 Time: 8:30 AM Eastern Time Conference Call: https://register.vevent.com/register/BI4e72dffa5a7b4167a28a33a6b3097df3 Webcast: https://edge.media-server.com/mmc/p/7uzqoye3 Â AboutÂ SHIELD IIÂ SHIELD IIÂ (Surgicalsite Hospital acquired Infection prEvention with Local D-PLEX) is a prospective, multinational, randomized, double blind Phase 3 trialdesigned to assess the efficacy and safety of D-PLEX100Â administered concomitantly with standard of care (â€œSoCâ€),which includes prophylactic systemic antibiotics, compared to SoC alone arm, in the prevention of post abdominal-surgery incisional infectionin patients undergoing abdominal colorectal surgeries with large incisions. The primary endpoint of the trial is measured by the proportionof subjects with either a surgical site infection (â€œSSIâ€) event as determined by a blinded and independent adjudication committee,reintervention, or mortality for any reason within 30 days post-surgery. Patient safety will be monitored for an additional 30 days. Thetrial will enroll patients in centers inÂ the United States,Â EuropeÂ andÂ Israel.Â AboutD-PLEX100Â D-PLEX100,Â PolyPidâ€™slead product candidate, is designed to provide local prolonged and controlled anti-bacterial activity directly at the surgical site toprevent SSIs. Following the administration of D-PLEX100Â into the surgical site, the PLEX (Polymer-Lipid EncapsulationmatriX) technology pairs with Active Pharmaceutical Ingredients, enabling a prolonged and continuous release of the broad-spectrum antibioticdoxycycline, resulting in a high local concentration of the drug for a period of 30 days for the prevention of SSIs, with additional potentialto prevent SSIs caused by antibiotic-resistant bacteria at the surgical site. D-PLEX100Â receivedÂ Breakthrough Therapy,Fast Track and Qualified Infectious Disease Product (QIDP) DesignationsÂ from theÂ U.S.Â Food and Drug Administration forthe prevention of SSIs in patients undergoing elective colorectal surgery. D-PLEX100Â is currently in Phase 3 SHIELD IIÂ trialfor the prevention of surgical site infections in patients undergoing abdominal colorectal surgery with large incisions.Â AboutÂ PolyPidÂ PolyPidLtd.Â (Nasdaq:Â PYPD)is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics,PolyPidâ€™s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs),enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPidâ€™s lead productcandidate D-PLEX100Â is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections.In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginningwith glioblastoma.Â For additional Companyinformation, please visitÂ http://www.polypid.comÂ andfollow us onÂ TwitterÂ andÂ LinkedIn.Â 3 Â Â Forward-looking StatementsÂ This press release containsâ€œforward-looking statementsâ€ within the meaning of the Private Securities Litigation Reform Act and other securities laws.Words such as â€œexpects,â€ â€œanticipates,â€ â€œintends,â€ â€œplans,â€ â€œbelieves,â€ â€œseeks,â€â€œestimatesâ€ and similar expressions or variations of such words are intended to identify forward-looking statements. Forexample, the Company is using forward-looking statements when it discusses the expected timing for completion of enrollment of the SHIELDII trial, expected timing for top-line results from the SHIELD II trial, potential NDA and MAA submissions, potential clinical benefitsof D-PLEX100, including safety and efficacy, and potential success of the trial, pre-launch activities and partnership discussions,that the gross proceeds from the financing extend the Companyâ€™s cash runway into the third quarter of 2025, that proceeds fromthe exercise of all warrants issued in the financing transaction would provide the Company with capital beyond NDA approval, that theCompany is well-positioned for a potentially transformational year in 2025, the potential of the Companyâ€™s collaboration with ImmunoGenesisto enhance treatment for solid tumors, and the expectation that the Companyâ€™s current cash balance will be sufficient to fund operationsinto the third quarter of 2025. Forward-looking statements are not historical facts, and are based upon managementâ€™s current expectations,beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressedin good faith. However, there can be no assurance that managementâ€™s expectations, beliefs and projections will be achieved, andactual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statementsare subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in theforward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made tothe Companyâ€™s reports filed from time to time with theÂ Securities and Exchange Commission, including, but not limited to,the risks detailed in the Companyâ€™s Annual Report on Form 20-F filed onÂ March 6, 2024. Forward-looking statements speak onlyas of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results,subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except tothe extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference shouldbe drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements.Â References and linksto websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference intothis press release.Â PolyPidÂ is not responsible for the contents of third-party websites.Â Contacts: PolyPid Ltd.Â Ori WarshavskyCOO â€“ US908-858-5995IR@Polypid.comÂ Investors:Brian RitchieLifeSci Advisors212-915-2578BRitchie@lifesciadvisors.comÂ 4 Â Â CONSOLIDATEDBALANCE SHEETSU.S.Â dollars in thousands Â Â Â

December 31,Â Â Â 2024Â Â 2023Â Â Â (Unaudited)Â Â Â Â ASSETSÂ Â Â Â Â Â Â Â Â Â Â Â Â CURRENT ASSETS:Â Â Â Â Â Â Cash and cash equivalentsÂ $15,641Â Â $5,309Â Restricted depositsÂ Â 168Â Â Â 300Â Prepaid expenses and other current assetsÂ Â 764Â Â Â 458Â Â Â Â Â Â Â Â Â Â Â Â Total current assetsÂ Â 16,573Â Â Â 6,067Â Â Â Â Â Â Â Â Â Â Â Â LONG-TERM ASSETS:Â Â Â Â Â Â Â Property and equipment, netÂ Â 6,075Â Â Â 7,621Â Operating lease right-of-use assetsÂ Â 2,295Â Â Â 1,597Â Other long-term assetsÂ Â 277Â Â Â 87Â Â Â Â Â Â Â Â Â Â Â Â Total long-term assetsÂ Â 8,647Â Â Â 9,305Â Â Â Â Â Â Â Â Â Â Â Â Total assetsÂ $25,220Â Â $15,372Â Â 5 Â Â CONSOLIDATEDBALANCE SHEETSU.S.Â dollars in thousands (except shareand per share data)Â Â Â December 31,Â Â Â 2024Â Â 2023Â Â Â (Unaudited)Â Â Â Â LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)Â Â Â Â Â Â Â Â Â Â Â Â CURRENT LIABILITIES:Â Â Â Â Â Â Trade payablesÂ $2,409Â Â $772Â Accrued expenses and other current liabilitiesÂ Â 2,566Â Â Â 1,971Â Current maturities of long-term debtÂ Â 6,787Â Â Â 4,003Â Current maturities of operating lease liabilitiesÂ Â 919Â Â Â 540Â Â Â Â Â Â Â Â Â Â Â Â Total current liabilitiesÂ Â 12,681Â Â Â 7,286Â Â Â Â Â Â Â Â Â Â Â Â LONG-TERM LIABILITIES:Â Â Â Â Â Â Â Long-term debtÂ Â 634Â Â Â 6,379Â Deferred revenuesÂ Â 2,548Â Â Â 2,548Â Long-term operating lease liabilitiesÂ Â 1,277Â Â Â 857Â Other liabilitiesÂ Â 396Â Â Â 398Â Â Â Â Â Â Â Â Â Â Â Â Total long-term liabilitiesÂ Â 4,855Â Â Â 10,182Â Â Â Â Â Â Â Â Â Â Â Â COMMITMENTS AND CONTINGENT LIABILITIES (NOTE 8)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â SHAREHOLDERS' EQUITY (DEFICIT):Â Â Â Â Â Â Â Ordinary shares, no par value - Authorized: 107,800,000 shares at December 31, 2024 and 2023, respectively; Issued and outstanding: 10,190,904 and 1,653,559 shares at December 31, 2024 and 2023, respectivelyÂ Â -Â Â Â -Â Additional paid-in capitalÂ Â 275,015Â Â Â 236,213Â Accumulated deficitÂ Â (267,331)Â Â (238,309) Â Â Â Â Â Â Â Â Â Â Â Â Total shareholders' equity (deficit)Â Â 7,684Â Â Â (2,096) Â Â Â Â Â Â Â Â Â Â Â Â Total liabilities and shareholders' equity (deficit)Â $25,220Â Â $15,372Â Â 6 Â Â CONSOLIDATED STATEMENTS OF OPERATIONSU.S.Â dollars in thousands (except shareand per share data)Â Â Â Year Ended December 31,Â Â Â 2024Â Â 2023Â Â 2022Â Â Â (Unaudited)Â Â Â Â Â Â Operating expenses:Â Â Â Â Â Â Â Â Â Â Research and development, netÂ $22,811Â Â $16,148Â Â $27,990Â Marketing and business developmentÂ Â 945Â Â Â 1,196Â Â Â 2,888Â General and administrativeÂ Â 4,273Â Â Â 5,523Â Â Â 8,010Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Operating lossÂ Â 28,029Â Â Â 22,867Â Â Â 38,888Â Financial expense, netÂ Â 951Â Â Â 929Â Â Â 540Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Loss before income taxÂ Â 28,980Â Â Â 23,796Â Â Â 39,428Â Income tax expenseÂ Â 42Â Â Â 69Â Â Â 129Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net lossÂ $29,022Â Â $23,865Â Â $39,557Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Loss per share *):Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â BasicÂ $4.91Â Â $16.99Â Â $61.09Â Â Â DilutedÂ $4.91Â Â $16.93Â Â $61.09Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Weighted-average Ordinary shares outstanding *):Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â BasicÂ Â 5,912,890Â Â Â 1,404,368Â Â Â 647,556Â Â Â DilutedÂ Â 5,912,890Â Â Â 1,421,308Â Â Â 647,556Â Â *)Resultsfor the year ended December 31, 2022, have been retroactively adjusted to reflect theÂ 1-for-30 reverse share split affectedon September 18, 2023.Â Â 7Â Â